I think Kazia currently haven’t applied for FTD for DIPG and this is implied in the below comment from the announcement today. (That is not to say they wont apply in the future though).
“...This award of ODD concludes a program of regulatory optimisation that Kazia has initiated for paxalisib over the past six months...”
Also, it might be worth noting that there likely will be some added benefit from the FTD process for glioblastoma for other indications as the marketing application would contain some similar components.
- Forums
- ASX - By Stock
- KZA
- Ann: Kazia's paxalisib awarded Orphan Drug Designation
Ann: Kazia's paxalisib awarded Orphan Drug Designation, page-16
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online